Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Is Attentive To ADHD: Tomoxetine Into Phase III; 2001 NDA Planned

Executive Summary

Tomoxetine for attention deficit hyperactivity disorder could be the next neuroscience entry from Lilly, building on the Prozac and Zyprexa franchises.

You may also be interested in...



Alza Concerta Climbs To 15% Of ADHD Market With 170,000 Patients

Alza Concerta holds 15% of the attention deficit hyperactive disorder market, Senior VP-Sales & Marketing Dan Swisher told the company's annual analyst meeting in New York City Feb. 27.

Alza Concerta Climbs To 15% Of ADHD Market With 170,000 Patients

Alza Concerta holds 15% of the attention deficit hyperactive disorder market, Senior VP-Sales & Marketing Dan Swisher told the company's annual analyst meeting in New York City Feb. 27.

FDA's Proposed Osteoporosis Definition For PTH Trials Questioned By Lilly

FDA's proposed limitations on clinical trial eligibility for parathyroid hormone osteoporosis studies are too restrictive, Lilly said in Aug. 4 comments on FDA's "Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis" draft guidance.

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel